Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467426 | 0.79 | MAP3K5 (0.54) | ROCK1ACVR1MAP3K5FDPSPCSK9 | |
| SCHEMBL830110 | 0.79 | ROCK1 (0.46) | ROCK1ACVR1MAP3K5FDPSPCSK9 | |
| SCHEMBL1133352 | 0.76 | KMT2A (0.48) | ROCK1ACVR1MAP3K5MEN1KMT2A | |
| SCHEMBL17822136 | 0.74 | CDK1 (0.34) | KDM4ECDK1CDK2 | |
| SCHEMBL167891 | 0.73 | MAP3K5 (0.60) | ROCK1MAP3K5MEN1KMT2ACYP1A2 | |
| SCHEMBL31381352 | 0.73 | MAP3K5 (0.60) | ROCK1MAP3K5MEN1KMT2ACYP1A2 | |
| Benzene SCHEMBL28188863 | 0.73 | MAP3K5 (0.60) | ROCK1MAP3K5MEN1KMT2ACYP1A2 | |
| SCHEMBL27770482 | 0.73 | MAP3K5 (0.60) | ROCK1MAP3K5MEN1KMT2ACYP1A2 | |
| SCHEMBL589542 | 0.72 | ACHE (0.36) | MEN1KMT2ACDK1CDK2 | |
| SCHEMBL5113027 | 0.72 | CRHBP (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611253-B2 | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith | AMBIT BIOSCIENCES CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611253-B2 | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith | AMBIT BIOSCIENCES CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611253-B2 | Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith | AMBIT BIOSCIENCES CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2611792-B1 | HYDROBROMIDE SALTS OF A PYRAZOLYLAMINOQUINAZOLINE | AMBIT BIOSCIENCES CORP (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2611795-B1 | AN OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016059149-A1 | METHOD OF TESTING SYSTEMIC RELEASE OF AZD1152 HQPA OR BIOEQUIVALENTS | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | WO | disclosed |
| EP-2611796-B1 | AN OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9295672-B2 | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295672-B2 | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295672-B2 | Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120053193-A1 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053193-A1 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053194-A1 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053195-A1 | HYDROBROMIDE SALTS OF A PYRAZOLYLAMINOQUINAZOLINE | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20100196907-A1 | MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010088470-A1 | MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY | ABBOTT LABORATORIES (US) | 2010-08-05 | — | — | WO | disclosed |
| CN-101443339-A | Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group | ASTRAZENECA AB (SE) | 2009-05-27 | — | — | CN | disclosed |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1931639-A2 | PROCESS | Astra Zeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034183-A2 | PROCESS FOR THE PREPARATION OF 4-AMINOPYRAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053195-A1 | HYDROBROMIDE SALTS OF A PYRAZOLYLAMINOQUINAZOLINE | VHL, TP53, GLS | ROCK1 3719/4885ACVR1 4678/4885MAP3K5 1212/4885 |
| US-20120053194-A1 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK3, JAK2 | ROCK1 288/4885ACVR1 2268/4885MAP3K5 31/4885 |
| US-20080269500-A1 | Process for the Preparation of 4-Aminopyrazole Derivatives | CYP3A4, CYP3A43, CYP3A5 | ROCK1 4284/4885ACVR1 3630/4885MAP3K5 465/4885 |
| US-20120053193-A1 | OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK3, JAK2 | ROCK1 288/4885ACVR1 2421/4885MAP3K5 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.